Uniseed has upped its investment in probiotic drink maker Perkii after leading the Queensland spinout’s first $3m round in 2016.

Harvard’s Quralis has added funding from investors including Viva Biotech to take its seed total to $5.5m as it looks to advance treatments for amyotrophic lateral sclerosis to the clinic.

PellePharm has signed a $760m agreement with Leo Pharma to create therapies for skin cancers, with Leo investing $70m in a first tranche and securing an option to wholly acquire PellePharm.

Oxford spinout OMass has pivoted from offering consulting services to developing its own drugs after closing a series A round backed by Oxford Sciences Innovation.

Synthorx, spun out of Scripps Research Institute, is targeting $100m in a proposed offering half a year after it raised $63m in a series C round backed by Osage University Partners.

Novartis Venture Fund returned to reinvest in inflammatory disease drug developer Inflazome as part of its $45.6m series B round.

The biopharmaceutical spinout of University of Veterinary Medicine Vienna is issuing 400,000 shares in an initial public offering that is set to fetch between $34m and $41m.

Inflammatory disease drug developer Inflazome, based on research at University of Queensland and Trinity College Dublin, has added $45.6m in series B capital to its coffers.

Vascugen has collected an undisclosed sum from investors including Indiana University Philanthropic Venture Fund to commercialise medicines for vascular-degenerative diseases based on IU technology.

The Kaiser Permanente-backed medical device producer upscaled its initial public offering to $64.4m after the underwriters took up the over-allotment option.